ICON Announces Appointment of Mr. Eugene McCague to Board of Directors
04 Octobre 2017 - 12:00PM
Business Wire
ICON plc, (NASDAQ: ICLR) global provider of drug
development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced the
appointment of Mr. Eugene McCague as a non-executive director.
Mr. McCague was a corporate partner of Arthur Cox, one of
Ireland’s premier law firms, from 1988 until June 2017. During his
time with Arthur Cox, Mr. McCague served as both managing partner
and chairman of Arthur Cox and also advised a wide range of public
and private companies on mainstream corporate work, mergers and
acquisitions, corporate restructurings and corporate
governance.
In addition to his distinguished legal career, Mr. McCague also
has extensive board experience with commercial, government and
educational organizations. Mr. McCague currently serves on the
board of FLY Leasing Limited, an aircraft leasing company listed on
the New York Stock Exchange, and on the board of the Irish branch
of AON Insurance. He also serves as chairman of the governing
authority of University College Dublin.
Mr. McCague’s previous board roles include the Health Service
Executive, the Irish state body which administers public health
service in Ireland, chairman of the governing body of Dublin
Institute of Technology and chairman of the Dublin Institute of
Technology Foundation. Mr. McCague was also president of the Dublin
Chamber of Commerce in 2006.
Mr. McCague holds a Bachelor of Civil Law degree and a diploma
in European Law from University College Dublin.
"I am very pleased that Eugene has joined the board," commented
Mr. Ciaran Murray, Chairman of the Board. "His leadership positions
at Arthur Cox, one of Ireland’s premier law firms, and his strong
business experience across many industry sectors will bring
invaluable expertise to the ICON board.”
About ICON plc
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON currently,
operates from 97 locations in 38 countries and has approximately
13,100 employees.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON/ICLR-F
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171004005577/en/
ICONInvestor Relations1-888-381-7923orBrendan Brennan Chief
Financial Officer+ 353 –1-291-2000orJonathan Curtain Vice President
Corporate Finance & Investor Relations+1-215-616-3000
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
ICON (NASDAQ:ICLR)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024